Genenta Science S.p.A.
GNTA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.62
KIRA · Stoqly’s AI analyst, in plain words
- Genenta Science S.p.A. lost $7.4M in fiscal 2025.
- Free cash flow was −$7.8M in fiscal 2025, — of revenue.
Market cap
$12.3M
P/E
—
Revenue
—
Net income
−$7.4M
Free cash flow
−$7.8M
Operating margin
—
Genenta Science S.p.A. in 30 seconds · fiscal 2025
Does it make a profit?
−$7.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Genenta Science S.p.A. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 1, 2026
- Legal name
- Genenta Science S.p.A.
- CIK
- 0001838716
Genenta Science S.p.A. · GNTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$6.5M | −$8.9M | −$12.6M | −$9.6M | −$7.4M |
| Diluted EPS | −$0.44 | −$0.49 | −$0.69 | −$0.53 | −$0.37 |
| Cash | |||||
| Cash from operations | −$8.2M | −$7.8M | −$12.1M | −$6.8M | −$7.7M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.2M | −$7.8M | −$12.1M | −$6.8M | −$7.8M |
| Share count change | — | 20.8% | 0.0% | 0.3% | 7.9% |
| Debt and strength | |||||
| Cash and short-term investments | $42.2M | $31.8M | $20.7M | $13.2M | $33.1M |
| Shareholders' equity | $44.0M | $33.2M | $22.6M | $13.0M | $25.7M |
| Current ratio | 34.1x | 14.5x | 12.2x | 6.9x | 14.2x |
| Returns and quality | |||||
| Return on equity | −20.9% | −23.1% | −45.1% | −54.2% | −38.1% |
| Return on tangible equity | −14.9% | −26.9% | −55.8% | −74.3% | −28.7% |
| Altman Z'' | 38.0 | 14.4 | 6.6 | −5.8 | 0.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Genenta Science S.p.A. · GNTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.62 a share, the company is worth $12.3M.
Source: SEC EDGAR XBRL filings (CIK 0001838716). Data updated October 24, 2026. Filed in EUR under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.